MANNITOL
Hyperlipidemias
Pichamol Jirapinyo, MD, MPHSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Hyperlipidemias cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
SIMVASTATIN National University Hospital, Singapore | Phase 4 | BB |
Alirocumab Population Health Research Institute | Phase 2 | B |
Gly-Low Hoskinson Health and Wellness Clinic | Early Phase 1 | CC |
Apple Cider Vinegar Western University | Early Phase 1 | C |
LACTULOSE Pichamol Jirapinyo, MD, MPH | D | |
Sucralose Pichamol Jirapinyo, MD, MPH | D | |
ALLERGENIC EXTRACT- APPLE MALUS SP University of Guelph | N/A | D |
Same molecule, other indications
MANNITOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →